JP2018501237A - ジアリールチオヒダントイン化合物を調製するためのプロセス - Google Patents
ジアリールチオヒダントイン化合物を調製するためのプロセス Download PDFInfo
- Publication number
- JP2018501237A JP2018501237A JP2017532725A JP2017532725A JP2018501237A JP 2018501237 A JP2018501237 A JP 2018501237A JP 2017532725 A JP2017532725 A JP 2017532725A JP 2017532725 A JP2017532725 A JP 2017532725A JP 2018501237 A JP2018501237 A JP 2018501237A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- temperature
- organic solvent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 171
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 238000000034 method Methods 0.000 claims abstract description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000003960 organic solvent Substances 0.000 claims description 39
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 26
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- -1 TBD Chemical compound 0.000 claims description 21
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 19
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- KOSYAAIZOGNATQ-UHFFFAOYSA-N o-phenyl chloromethanethioate Chemical compound ClC(=S)OC1=CC=CC=C1 KOSYAAIZOGNATQ-UHFFFAOYSA-N 0.000 claims description 14
- 150000007530 organic bases Chemical class 0.000 claims description 14
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 13
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 10
- 239000010949 copper Substances 0.000 claims description 10
- 235000011056 potassium acetate Nutrition 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 9
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims description 9
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 7
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 7
- 235000019439 ethyl acetate Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- KXMMNJQMGILZDB-UHFFFAOYSA-N 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one Chemical group O=C1C=CC=CN1C(=S)N1C(=O)C=CC=C1 KXMMNJQMGILZDB-UHFFFAOYSA-N 0.000 claims description 6
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 6
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 6
- 150000001879 copper Chemical class 0.000 claims description 6
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 claims description 6
- 239000012973 diazabicyclooctane Substances 0.000 claims description 6
- 150000007529 inorganic bases Chemical class 0.000 claims description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 239000002002 slurry Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008096 xylene Substances 0.000 claims description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 5
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 5
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 5
- 239000007822 coupling agent Substances 0.000 claims description 5
- 229940045803 cuprous chloride Drugs 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- OEBXWWBYZJNKRK-UHFFFAOYSA-N 1-methyl-2,3,4,6,7,8-hexahydropyrimido[1,2-a]pyrimidine Chemical compound C1CCN=C2N(C)CCCN21 OEBXWWBYZJNKRK-UHFFFAOYSA-N 0.000 claims description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 claims description 4
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 238000010976 amide bond formation reaction Methods 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 claims description 4
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 4
- 125000002346 iodo group Chemical group I* 0.000 claims description 4
- 239000012948 isocyanate Substances 0.000 claims description 4
- 150000002513 isocyanates Chemical class 0.000 claims description 4
- 230000000269 nucleophilic effect Effects 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- MWPOEMYVTCIOPT-UHFFFAOYSA-N pyridin-2-yloxymethanethioic s-acid Chemical compound SC(=O)OC1=CC=CC=N1 MWPOEMYVTCIOPT-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 claims description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 4
- KFYRJJBUHYILSO-YFKPBYRVSA-N (2s)-2-amino-3-dimethylarsanylsulfanyl-3-methylbutanoic acid Chemical compound C[As](C)SC(C)(C)[C@@H](N)C(O)=O KFYRJJBUHYILSO-YFKPBYRVSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexyloxide Natural products O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims description 3
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- SJRDNQOIQZOVQD-UHFFFAOYSA-M sodium;2,2-dimethylpropanoate Chemical compound [Na+].CC(C)(C)C([O-])=O SJRDNQOIQZOVQD-UHFFFAOYSA-M 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 2
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 claims description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 claims description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012964 benzotriazole Substances 0.000 claims description 2
- KUSNXMZPSJPTRZ-UHFFFAOYSA-N bis(2h-benzotriazol-4-yl)methanethione Chemical compound C1=CC2=NNN=C2C(C(C=2C3=NNN=C3C=CC=2)=S)=C1 KUSNXMZPSJPTRZ-UHFFFAOYSA-N 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Inorganic materials [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000003791 organic solvent mixture Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 239000012298 atmosphere Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229940001482 sodium sulfite Drugs 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- NRTLTGGGUQIRRT-UHFFFAOYSA-N triethylazanium;bromide Chemical compound [Br-].CC[NH+](CC)CC NRTLTGGGUQIRRT-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- AOIBEJROTGNTND-UHFFFAOYSA-N 5-isocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N(=C=O)C=1C=C(C(=NC=1)C#N)C(F)(F)F AOIBEJROTGNTND-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
- B01J27/198—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
本出願は米国特許仮出願第62/094,436号(2014年12月19日出願)に対する優先権を主張し、その全体が参照により本明細書に組み込まれる。
下に記載される本発明の研究及び開発は、連邦政府の支援によるものではない。
本発明は、化合物(X)の調製及びその合成における中間体の調製に関する。さらに具体的には、本発明は、2013年5月21日に登録され、その全体が参照により本明細書に組み込まれる米国特許第8,445,507号に開示される、化合物(X)を調製するためのプロセスに関する。
本発明の全体的なスキームを以下のスキームAに示す。
以下の実施例は、本発明の理解を助けるために記載するものであり、本明細書に付属する「特許請求の範囲」に記載される発明をいかなる意味においても限定することを目的としたものではなく、またそのように解釈されるべきではない。
1.00gの5% Pt/C触媒F101 R/W(Evonik AG製、約60%の水を含有する)及び4.0mLの脱イオン水のスラリーに、20mLのガラスビーカー中、0.156g(0.129mL、50% w/w)のH3PO2を加えた。磁気攪拌棒を用いて攪拌しながら15分後、58mgのNH4VO3を加え、スラリーを再び15分間攪拌した。
100mLのオートクレーブに、10.0gの化合物(III)(46.1mmol)を26.7mLのキシレン及び13.3mLのブチロニトリルに溶かした溶液を投入した。この溶液に、2mLの脱イオン水を用いつつ、改質された触媒スラリーを加えた。オートクレーブを閉じ、次いで、窒素を用いて10barまで3回加圧することによって不活性化し、水素を用いて10barまで3回加圧した。反応器の圧力を水素5.0barに設定し、攪拌を開始し(中空シャフトタービン撹拌機、1200rpm)、混合物を50分以内に70℃まで加熱した。70℃に達したらすぐに、水素の取り込みが止まった。さらに40分間攪拌した後、加熱を止め、オートクレーブを冷却した。スラリーをファイバーガラスフィルタに通して濾過し、40mLのキシレンを用い、20〜23℃で何回かにわけて洗浄した。ブチロニトリル溶媒を蒸発させ、溶液から化合物(IV)を結晶化させた。1H NMR(300MHz,DMSO−d6)δ 8.20(d,J=2.4Hz,1H),7.31(d,J=2.6Hz,1H),7.04(s,NH)。
方法A.反応器に、48gの化合物(XVII)、52.8gの1,1’−チオカルボニルビス(ピリジン−2(1H)−オン)、13.5gの4−ジメチルアミノピリジン、144mLのDMAを投入した。混合物を攪拌し、2時間かけて90℃まで加熱した。次いで、反応物を60℃まで冷却した。体積37mLのHCl(イソプロパノール中6M)を加え、その後、144mLのイソプロパノール及び216mLの水を加えた。濾過によって化合物(X)を収率80%で単離した。
Claims (30)
- 化合物(X)を調製するためのプロセスであって、
を含む、プロセス。 - 請求項1に記載のプロセスであって、工程(2a)が、さらに、
- 前記アミドカップリング剤が1,1−カルボニルジイミダゾールであり、前記触媒がDBUである、請求項2に記載のプロセス。
- 請求項1に記載のプロセスであって、工程(2a−1)が、さらに、
を含む、プロセス。 - 請求項1に記載のプロセスであって、工程(2c)が、さらに、
を含む、プロセス。 - 請求項5に記載のプロセスであって、化合物(XIII)と、式(2c−1)の化合物とを、臭化第一銅存在下;TMEDA存在下;酢酸カリウム存在下;有機溶媒DMA中;約80℃〜約140℃の範囲の温度で反応させることを含む、プロセス。
- 請求項5に記載のプロセスであって、化合物(XIII)と、式(2c−1)の化合物とを、銅粉末又は銅スポンジである銅(0)源存在下;酢酸カリウム又はピバル酸ナトリウム存在下;有機溶媒DMSO中;約0℃〜約80℃の範囲の温度で反応させることを含む、プロセス。
- 請求項5に記載のプロセスであって、化合物(XIII)と、式(2c−1)の化合物とを、銅粉末又は銅スポンジである銅(0)源存在下;酢酸カリウム存在下;塩化第一銅、ヨウ化第一銅、臭化第一銅及び酢酸第一銅からなる群から選択される銅(I)塩を添加しつつ;有機溶媒DMSO中;約0℃〜約80℃の範囲の温度で反応させることを含む、プロセス。
- 請求項1に記載のプロセスであって、工程(2d)は、さらに、
を含む、プロセス。 - 請求項9に記載のプロセスであって、工程(2e)が、さらに、化合物(XVII)と、O,O’−ジ(ピリジン−2−イル)カルボノチオエート、1,1’−チオカルボニルビス(ピリジン−2(1H)−オン)、ジ(1H−イミダゾール−1−イル)メタンチオン、チオホスゲン、チオノクロロギ酸フェニル、O−(2−ナフチル)チオノクロロホルメート、トリルチオノクロロホルメート及びチオカルボニルビス(ベンゾトリアゾール)からなる群から選択されるチオカルボニル源とを;DMAP、NaH及びNaOHからなる群から選択される活性化剤存在下;DMA、DMF、トルエン、DMSO、ACN、THF、DCM、EtOAc、アセトン、MEK及びジオキサンからなる群から選択される有機溶媒中;場合によりトリエチルアミン又はDIPEAから選択される有機塩基存在下;約−20℃〜約100℃の範囲の温度で反応させ、対応する化合物(X)を得ることを含む、プロセス。
- 前記チオカルボニル源が、1,1’−チオカルボニルビス(ピリジン−2(1H)−オン)である、請求項10に記載のプロセス。
- 前記活性化剤がDMAPである、請求項11に記載のプロセス。
- 前記有機溶媒がDMAである、請求項12に記載のプロセス。
- 前記チオカルボニル源がチオノクロロギ酸フェニルであり;前記活性化剤がDMAPであり;前記有機塩基が、トリエチルアミン又はDIPEAであり;前記有機溶媒がDMAであり;約−20℃〜約80℃の範囲の温度である、請求項10に記載のプロセス。
- 前記チオカルボニル源がチオノクロロギ酸フェニルであり;前記活性化剤がDMAPであり;前記有機塩基が、トリエチルアミン又はDIPEAであり;前記有機溶媒が、アセトン又は酢酸エチルであり;約−20℃〜約80℃の範囲の温度である、請求項10に記載のプロセス。
- 環化直後にDMAPAが添加される、請求項15に記載のプロセス。
- 工程(2e)は、さらに、チオノクロロギ酸フェニルとDMAPとを反応させ、単離可能な四級塩化合物(S1)を生成すること;
を含む、請求項10に記載のプロセス。 - 請求項1に記載のプロセスであって、工程(2d)が、さらに、
を含む、プロセス。 - 請求項18に記載のプロセスであって、さらに、
式(2c−2B)の化合物と、O,O’−ジ(ピリジン−2−イル)カルボノチオエート、1,1’−チオカルボニルビス(ピリジン−2(1H)−オン)、ジ(1H−イミダゾール−1−イル)メタンチオン、チオホスゲン、チオノクロロギ酸フェニル、O−(2−ナフチル)チオノクロロホルメート、トリルチオノクロロホルメート及びチオカルボニルビス(ベンゾトリアゾール)からなる群から選択されるチオカルボニル源とを;DMAP、NaH及びNaOHからなる群から選択される活性化剤存在下;ジメチルアセトアミド、DMF、トルエン、DMSO、THF及びジオキサンからなる群から選択される有機溶媒中;約−20℃〜約100℃の範囲の温度で反応させ;式(2e)の対応する化合物を得ること;その後
式(2e)の前記化合物を、メチルアミンで;THF、DMF、DMA、エタノール及びこれらの水性混合物からなる群から選択される有機溶媒中;ほぼ周囲温度で処理し、対応する化合物(X)を得ること
をさらに含む、プロセス。 - 式(2e)の前記化合物をメチルアミンで処理することは、さらに、エタノールを有機溶媒として用いることを含む、請求項19に記載のプロセス。
- 請求項19に記載のプロセスであって、さらに、
前記チオカルボニル源がチオノクロロギ酸フェニルである式(2c−2B)の化合物を、前記活性化剤がDMAPであり;前記有機溶媒が、アセトン又は酢酸エチルであり;約−20℃〜40℃の範囲の温度で反応させ、式(2e)の対応する化合物を得ること;その後
式(2e)の前記化合物を、メチルアミンで;エタノール中;ほぼ室温で処理し;対応する化合物(X)を得ること
を含む、プロセス。 - 請求項18に記載のプロセスであって、工程(2f)が、さらに、
チオノクロロギ酸フェニルとDMAPとを反応させ、単離可能な四級塩化合物(S1)を生成すること
を含む、プロセス。 - 化合物(II)を調製するためのプロセスであって、
リン酸オキシブロミドのキシレン溶液を化合物(I)に加えること;
約3時間で約100℃まで加熱すること;次いで、
反応混合物を約70℃まで冷却した後、NaOHを加えて化合物(II)を得ること
を含む、プロセス。 - 化合物(III)を調製するためのプロセスであって、
- 化合物(IV)を調製するためのプロセスであって、
攪拌しながらNH4VO3をスラリーに約15分間で加えること;その後
化合物(III)と、前記触媒スラリーとを、キシレン及びブチロニトリルからなる群から選択される有機溶媒又は溶媒混合物中;不活性雰囲気下;水素ガス存在下;約70℃の温度で反応させ、化合物(IV)を得ること
を含む、プロセス。 - Pがアミノ保護基である化合物(X)の調製に有用な式(XII−c)の化合物。
- Pがt−ブトキシカルボニルである、請求項26に記載の化合物。
- 化合物(X)の調製に有用な化合物(XIII)。
- 化合物(X)の調製に有用な化合物(XVII)。
- 化合物(X)の調製に有用な式(2c−2B)の化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020052658A JP6903785B2 (ja) | 2014-12-19 | 2020-03-24 | ジアリールチオヒダントイン化合物を調製するためのプロセス |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462094436P | 2014-12-19 | 2014-12-19 | |
US62/094,436 | 2014-12-19 | ||
PCT/US2015/066356 WO2016100652A2 (en) | 2014-12-19 | 2015-12-17 | Process for the preparation of a diarylthiohydantoin compound |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020052658A Division JP6903785B2 (ja) | 2014-12-19 | 2020-03-24 | ジアリールチオヒダントイン化合物を調製するためのプロセス |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018501237A true JP2018501237A (ja) | 2018-01-18 |
JP6681902B2 JP6681902B2 (ja) | 2020-04-15 |
Family
ID=55168400
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017532725A Active JP6681902B2 (ja) | 2014-12-19 | 2015-12-17 | ジアリールチオヒダントイン化合物を調製するためのプロセス |
JP2020052658A Active JP6903785B2 (ja) | 2014-12-19 | 2020-03-24 | ジアリールチオヒダントイン化合物を調製するためのプロセス |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020052658A Active JP6903785B2 (ja) | 2014-12-19 | 2020-03-24 | ジアリールチオヒダントイン化合物を調製するためのプロセス |
Country Status (33)
Country | Link |
---|---|
US (1) | US9688655B2 (ja) |
EP (4) | EP3372584B9 (ja) |
JP (2) | JP6681902B2 (ja) |
KR (1) | KR102586059B1 (ja) |
CN (1) | CN107108507B (ja) |
AR (1) | AR103228A1 (ja) |
AU (1) | AU2015364537B2 (ja) |
BR (1) | BR112017013113B1 (ja) |
CA (1) | CA2970937A1 (ja) |
CY (2) | CY1121684T1 (ja) |
DK (3) | DK3372584T5 (ja) |
EA (4) | EA201892487A1 (ja) |
ES (3) | ES2718539T3 (ja) |
HR (3) | HRP20220750T1 (ja) |
HU (2) | HUE042409T2 (ja) |
IL (1) | IL252843A0 (ja) |
LT (3) | LT3372584T (ja) |
MA (1) | MA41200B1 (ja) |
MD (1) | MD3233803T2 (ja) |
ME (1) | ME03420B (ja) |
MX (1) | MX2017008179A (ja) |
NZ (1) | NZ732766A (ja) |
PH (1) | PH12017501152A1 (ja) |
PL (3) | PL3372584T3 (ja) |
PT (3) | PT3372585T (ja) |
RS (3) | RS61060B9 (ja) |
SG (4) | SG10201912811QA (ja) |
SI (3) | SI3233803T1 (ja) |
TR (1) | TR201904739T4 (ja) |
TW (4) | TWI753336B (ja) |
UA (1) | UA123201C2 (ja) |
WO (1) | WO2016100652A2 (ja) |
ZA (1) | ZA201704877B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020114842A (ja) * | 2014-12-19 | 2020-07-30 | アラゴン ファーマシューティカルズ,インコーポレイテッド | ジアリールチオヒダントイン化合物を調製するためのプロセス |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA122404C2 (uk) | 2014-12-19 | 2020-11-10 | Араґон Фармасьютікалз, Інк. | Способи одержання сполуки діарилтіогідантоїну |
CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
CN108383749B (zh) * | 2018-01-30 | 2021-03-09 | 杭州科巢生物科技有限公司 | 阿帕鲁胺的合成方法及其中间体 |
US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法 |
CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式(viii)的恩杂鲁胺的制备方法 |
CN110511207A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
CN110511206A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
EP4208451A1 (en) | 2020-09-04 | 2023-07-12 | Synthon B.V. | Improved process for preparation of apalutamide |
CN113292535B (zh) * | 2021-06-18 | 2022-07-01 | 南京方生和医药科技有限公司 | 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法 |
CN113402466B (zh) * | 2021-06-18 | 2022-08-16 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 |
CN115850233A (zh) * | 2021-09-24 | 2023-03-28 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺的合成方法 |
CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
CN117645572A (zh) * | 2023-11-23 | 2024-03-05 | 奥锐特药业股份有限公司 | 恩扎卢胺及其中间体的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
CA2908326A1 (en) * | 2013-05-29 | 2014-12-04 | Hinova Pharmaceuticals Inc. | Imidazolidinedione compounds and their uses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
DK2656841T3 (en) | 2006-03-27 | 2016-12-05 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
PE20141375A1 (es) * | 2008-05-16 | 2014-10-23 | Takeda San Diego Inc | Activadores de glucoquinasa |
PL2509961T3 (pl) | 2009-12-11 | 2016-09-30 | Pochodne imidazolidynodionu | |
WO2011103202A2 (en) * | 2010-02-16 | 2011-08-25 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
EP2538785B1 (en) * | 2010-02-24 | 2018-03-21 | Medivation Prostate Therapeutics LLC | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
CA2829322C (en) | 2011-03-10 | 2017-01-10 | Suzhou Kintor Pharmaceuticals, Inc. | Substituted thioimidazolidinone androgen receptor antagonists and uses thereof |
WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
CN104379160A (zh) * | 2012-03-29 | 2015-02-25 | 桑加特公司 | 双阿司匹林交联聚乙二醇化血红蛋白 |
NZ732766A (en) * | 2014-12-19 | 2023-07-28 | Aragon Pharmaceuticals Inc | Process for the preparation of a diarylthiohydantoin compound |
-
2015
- 2015-12-17 NZ NZ732766A patent/NZ732766A/en unknown
- 2015-12-17 WO PCT/US2015/066356 patent/WO2016100652A2/en active Application Filing
- 2015-12-17 EA EA201892487A patent/EA201892487A1/ru unknown
- 2015-12-17 DK DK18169756.6T patent/DK3372584T5/da active
- 2015-12-17 ES ES15823875T patent/ES2718539T3/es active Active
- 2015-12-17 DK DK15823875.8T patent/DK3233803T3/en active
- 2015-12-17 MD MDE20170208T patent/MD3233803T2/ro unknown
- 2015-12-17 EA EA201791390A patent/EA201791390A1/ru unknown
- 2015-12-17 DK DK18169895.2T patent/DK3372585T3/da active
- 2015-12-17 SI SI201530599T patent/SI3233803T1/sl unknown
- 2015-12-17 UA UAA201707588A patent/UA123201C2/uk unknown
- 2015-12-17 PT PT181698952T patent/PT3372585T/pt unknown
- 2015-12-17 ME MEP-2019-86A patent/ME03420B/me unknown
- 2015-12-17 AU AU2015364537A patent/AU2015364537B2/en active Active
- 2015-12-17 LT LTEP18169756.6T patent/LT3372584T/lt unknown
- 2015-12-17 RS RS20201378A patent/RS61060B9/sr unknown
- 2015-12-17 EP EP18169756.6A patent/EP3372584B9/en active Active
- 2015-12-17 HU HUE15823875A patent/HUE042409T2/hu unknown
- 2015-12-17 LT LTEP18169895.2T patent/LT3372585T/lt unknown
- 2015-12-17 JP JP2017532725A patent/JP6681902B2/ja active Active
- 2015-12-17 HR HRP20220750TT patent/HRP20220750T1/hr unknown
- 2015-12-17 SG SG10201912811QA patent/SG10201912811QA/en unknown
- 2015-12-17 EA EA201892486A patent/EA201892486A1/ru unknown
- 2015-12-17 PL PL18169756T patent/PL3372584T3/pl unknown
- 2015-12-17 SG SG10201912805SA patent/SG10201912805SA/en unknown
- 2015-12-17 ES ES18169756T patent/ES2827549T3/es active Active
- 2015-12-17 US US14/973,089 patent/US9688655B2/en active Active
- 2015-12-17 EP EP18170050.1A patent/EP3372586A1/en not_active Withdrawn
- 2015-12-17 HU HUE18169756A patent/HUE052475T2/hu unknown
- 2015-12-17 EP EP18169895.2A patent/EP3372585B1/en active Active
- 2015-12-17 MX MX2017008179A patent/MX2017008179A/es active IP Right Grant
- 2015-12-17 RS RS20220542A patent/RS63455B1/sr unknown
- 2015-12-17 CA CA2970937A patent/CA2970937A1/en active Pending
- 2015-12-17 SG SG11201704969QA patent/SG11201704969QA/en unknown
- 2015-12-17 LT LTEP15823875.8T patent/LT3233803T/lt unknown
- 2015-12-17 ES ES18169895T patent/ES2919951T3/es active Active
- 2015-12-17 EP EP15823875.8A patent/EP3233803B1/en active Active
- 2015-12-17 BR BR112017013113-7A patent/BR112017013113B1/pt active IP Right Grant
- 2015-12-17 PT PT181697566T patent/PT3372584T/pt unknown
- 2015-12-17 MA MA41200A patent/MA41200B1/fr unknown
- 2015-12-17 KR KR1020177019551A patent/KR102586059B1/ko active IP Right Grant
- 2015-12-17 PL PL15823875T patent/PL3233803T3/pl unknown
- 2015-12-17 SG SG10201912802XA patent/SG10201912802XA/en unknown
- 2015-12-17 RS RS20190350A patent/RS58454B1/sr unknown
- 2015-12-17 SI SI201531848T patent/SI3372585T1/sl unknown
- 2015-12-17 PL PL18169895.2T patent/PL3372585T3/pl unknown
- 2015-12-17 SI SI201531433T patent/SI3372584T1/sl unknown
- 2015-12-17 CN CN201580069602.5A patent/CN107108507B/zh active Active
- 2015-12-17 TR TR2019/04739T patent/TR201904739T4/tr unknown
- 2015-12-17 EA EA201892485A patent/EA201892485A1/ru unknown
- 2015-12-17 PT PT15823875T patent/PT3233803T/pt unknown
- 2015-12-18 TW TW108146841A patent/TWI753336B/zh active
- 2015-12-18 TW TW104142692A patent/TWI683810B/zh active
- 2015-12-18 TW TW108131623A patent/TWI689494B/zh active
- 2015-12-18 TW TW108131622A patent/TWI703132B/zh active
- 2015-12-21 AR ARP150104237A patent/AR103228A1/es unknown
-
2017
- 2017-06-12 IL IL252843A patent/IL252843A0/en unknown
- 2017-06-19 PH PH12017501152A patent/PH12017501152A1/en unknown
- 2017-07-18 ZA ZA2017/04877A patent/ZA201704877B/en unknown
-
2019
- 2019-03-19 HR HRP20190540TT patent/HRP20190540T1/hr unknown
- 2019-04-10 CY CY20191100400T patent/CY1121684T1/el unknown
-
2020
- 2020-03-24 JP JP2020052658A patent/JP6903785B2/ja active Active
- 2020-11-02 CY CY20201101031T patent/CY1123611T1/el unknown
- 2020-11-20 HR HRP20201847TT patent/HRP20201847T2/hr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
CA2908326A1 (en) * | 2013-05-29 | 2014-12-04 | Hinova Pharmaceuticals Inc. | Imidazolidinedione compounds and their uses |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020114842A (ja) * | 2014-12-19 | 2020-07-30 | アラゴン ファーマシューティカルズ,インコーポレイテッド | ジアリールチオヒダントイン化合物を調製するためのプロセス |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6903785B2 (ja) | ジアリールチオヒダントイン化合物を調製するためのプロセス | |
CA3210320A1 (en) | Synthesis of a bruton's tyrosine kinase inhibitor | |
JP6696986B2 (ja) | ジアリールチオヒダントイン化合物の調製方法 | |
JP2017088632A (ja) | ベンズアミド化合物の合成に有用な化合物 | |
JP2021119142A (ja) | キサンチンをベースとする化合物の調製方法 | |
EP3421456A1 (en) | New route of synthesis for opicapone | |
TWI617562B (zh) | 用於由4-胺基-2,5-二甲氧基嘧啶製備2-胺基-5,8-二甲氧基[1,2,4]三唑并[1,5-c]嘧啶的改良方法 | |
US20160176844A1 (en) | Processes for the preparation of a diarylthiohydantoin compound | |
JP6777542B2 (ja) | 置換尿素化合物の合成のためのプロセス | |
EA041899B1 (ru) | Способ получения соединения диарилтиогидантоина | |
El Janati et al. | SYNTHESIS OF NEW HETEROCYCLIC SYSTEMS CONTAINING QUINOXALINE MOIETY | |
TW201200500A (en) | Process for the preparation of benzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181214 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200303 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6681902 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |